Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) just unveiled an announcement.
ResMed Inc. has reported a change in beneficial ownership as disclosed in a recent Form 4 filing. Michael J. Rider, the Global General Counsel, executed a transaction involving the sale of 50 shares of ResMed common stock at a price of $281.90 per share, under a Rule 10b5-1 plan adopted earlier in the year. This transaction reflects the company’s adherence to regulatory requirements and may have implications for its stock market performance and investor relations.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$41.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, specializing in the development and manufacturing of equipment related to sleep disorders and respiratory care. The company focuses on providing innovative solutions for patients with sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Average Trading Volume: 869,315
Technical Sentiment Signal: Buy
Current Market Cap: A$64.19B
Learn more about RMD stock on TipRanks’ Stock Analysis page.